Core Viewpoint - Soleno Therapeutics, Inc. has announced a public offering of 2,352,941 shares of common stock priced at $85.00 per share, aiming to raise approximately $200 million before expenses [1][3]. Group 1: Offering Details - The public offering consists of 2,352,941 shares, with an additional 30-day option for underwriters to purchase up to 352,941 more shares at the same price [1]. - The offering is expected to close on or about July 11, 2025, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds will primarily fund the commercialization of VYKAT XR, the first approved therapy for hyperphagia in Prader-Willi syndrome, which received FDA approval on March 26, 2025 [3]. - Additional proceeds will support regulatory and market development activities in the EU, further R&D efforts, and general corporate purposes, including working capital and potential acquisitions [3]. Group 3: Underwriters - Goldman Sachs & Co. LLC, Guggenheim Securities, TD Cowen, Cantor, and Oppenheimer & Co. are serving as joint book-running managers for the offering [2]. Group 4: Company Overview - Soleno Therapeutics focuses on developing novel therapeutics for rare diseases, with VYKAT XR being its first commercial product aimed at treating hyperphagia in individuals aged 4 and older with Prader-Willi syndrome [6].

Core Viewpoint - Soleno Therapeutics, Inc. plans to offer and sell $200 million of its common stock in an underwritten public offering, with an additional option for underwriters to purchase up to $30 million more [1][2]. Group 1: Offering Details - The public offering is subject to market conditions, and there is no assurance regarding the completion or terms of the offering [1]. - Goldman Sachs & Co. LLC and Guggenheim Securities are acting as the joint book-running managers for the offering [2]. - The shares will be offered under a registration statement previously filed with the SEC, and a preliminary prospectus will be made available [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to fund the commercialization of VYKAT™ XR, the first approved therapy for hyperphagia in Prader-Willi syndrome, which received FDA approval on March 26, 2025 [3]. - Proceeds will also support regulatory and market development activities in the EU, further R&D efforts, and general corporate purposes, including working capital and potential acquisitions [3][6].

Company Overview - Rhythm Pharmaceuticals, Inc. is a global, commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases [1] Proposed Offering - Rhythm announced a proposed public offering of $150 million of its common stock, with an additional option for underwriters to purchase up to $22.5 million of shares [1][2] - The offering is subject to market conditions and customary closing conditions, with no assurance on completion or terms [2] Regulatory Compliance - The offering is made under a shelf registration statement on Form S-3, which became effective on March 2, 2023 [3] - A preliminary prospectus supplement will be filed with the SEC and available on their website [3] Contact Information - Investor relations contact is David Connolly, Head of Investor Relations and Corporate Communications, reachable at 857-264-4280 [6]

Core Viewpoint - Borr Drilling Limited plans to raise $100 million through a public offering of approximately 50 million shares for general corporate purposes [1] Group 1: Offering Details - The offering will be conducted under an effective shelf registration statement filed with the SEC on April 11, 2025 [3] - The offering is expected to include two settlements: 30 million shares on July 7, 2025, and 20 million shares on August 7, 2025, contingent on a special general meeting [4] - Certain officers and directors of the Company, including Mr. Tor Olav Trøim, Mr. Patrick Schorn, and Mr. Bruno Morand, have indicated intentions to purchase shares totaling $11.3 million [5] Group 2: Underwriters - DNB Carnegie, Clarksons Securities, Citigroup, and Goldman Sachs & Co. LLC are the joint bookrunners for the offering [2]

Core Viewpoint - ArriVent BioPharma, Inc. plans to offer and sell $75 million of its common stock and pre-funded warrants, with a potential additional 15% option for underwriters, to support its drug development and general corporate purposes [1][2]. Group 1: Offering Details - The public offering includes $75 million in common stock and pre-funded warrants, with a 30-day option for underwriters to purchase an additional 15% [1]. - Goldman Sachs, Citigroup, and Guggenheim Securities are the joint book-running managers for the offering [2]. - An automatic shelf registration statement was filed with the SEC on February 3, 2025, which became effective upon filing [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to support activities related to firmonertinib and other pipeline programs, as well as for working capital and general corporate purposes [2]. Group 3: Company Overview - ArriVent is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer treatment, with a strong emphasis on its lead candidate, firmonertinib [5].

Group 1 - Sonim Technologies, Inc. announced a public offering of 7,400,000 shares of common stock at a price of $0.75 per share, with expected gross proceeds of approximately $5.55 million [1][2] - The company intends to use the net proceeds for operations supporting its overall business strategy, working capital, and potentially for repayment and refinancing of its indebtedness [2] - Roth Capital Partners is acting as the exclusive placement agent for the offering [2] Group 2 - The offering is being conducted under a registration statement on Form S-1, which was declared effective by the SEC on June 30, 2025 [3] - A preliminary prospectus has been filed with the SEC, and electronic copies of the final prospectus will be available on the SEC's website [3] - Sonim Technologies is recognized as a leading provider of rugged mobile solutions, serving various sectors including first responders and Fortune 500 companies since 1999 [5]

SARASOTA, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has entered into a placement agency agreement for the purchase and sale of up to 800,000 shares of the Company’s Series H Convertible Preferred Stock (“Preferred Stock”), no par value, and Warrants to purchase up to an additional 800,000 shares of Preferred Stock of the Company at an ex ...

Core Viewpoint - Raytech Holding Limited has announced a public offering of 25,985,000 ordinary shares priced at $0.20 per share, aiming to raise approximately $5.197 million before expenses [1][2]. Company Overview - Raytech Holding Limited is a Hong Kong-based company with over 10 years of experience in the personal care electrical appliance industry, specializing in design, sourcing, and wholesale for international brand owners [5]. - The company offers a diverse range of personal care electrical appliances, including hair styling tools, trimmers, eyelash curlers, neck care, and nail care products [5]. Offering Details - The public offering is expected to close on July 1, 2025, subject to customary closing conditions [2]. - R.F. Lafferty & Co., Inc. is acting as the sole placement agent for the offering, while Loeb & Loeb LLP and Zarif Law Group P.C. are providing legal counsel [2][3]. - The offering is conducted under a registration statement on Form F-1, which was declared effective by the U.S. Securities and Exchange Commission on June 30, 2025 [3].

Core Viewpoint - Nektar Therapeutics has announced a public offering of $100 million in common stock, pricing the shares at $23.50 each, with the offering expected to close on July 2, 2025 [1][2]. Group 1: Offering Details - Nektar is selling 4,255,320 shares in the offering, with gross proceeds anticipated to be approximately $100 million before expenses [1]. - The underwriters have a 30-day option to purchase an additional 638,298 shares at the public offering price [1]. - Jefferies and Piper Sandler are the joint bookrunning managers, with BTIG, LLC as the passive bookrunner and H.C. Wainwright & Co. as co-manager [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for general corporate purposes, including research and development, clinical development, and manufacturing costs to support drug candidates [2]. Group 3: Company Overview - Nektar Therapeutics is focused on developing innovative treatments for autoimmune and chronic inflammatory diseases, with its lead product candidate being rezpegaldesleukin (REZPEG, or NKTR-358) [6]. - The company is conducting two Phase 2b clinical trials for REZPEG, targeting atopic dermatitis and alopecia areata [6]. - Nektar's pipeline includes additional candidates such as NKTR-255, an investigational IL-15 receptor agonist, and other preclinical programs [6].

Core Viewpoint - Ascent Solar Technologies, Inc. has successfully closed a public offering of 1,000,000 shares of common stock and warrants, raising a total of $2.0 million for various corporate purposes [1][2]. Group 1: Offering Details - The public offering price was set at $2.00 per share, with the same price for the accompanying warrants, which have an exercise price of $2.00 and are exercisable immediately [1]. - The offering was facilitated by H.C. Wainwright & Co. as the exclusive placement agent [2]. - The gross proceeds from the offering amounted to $2.0 million before deducting fees and expenses [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated for working capital, product development activities, general administrative expenses, and other corporate purposes [2]. Group 3: Company Background - Ascent Solar Technologies is recognized for its innovative, high-performance, flexible thin-film solar panels, supported by 40 years of research and development and 15 years of manufacturing experience [5]. - The company's photovoltaic modules have been utilized in various applications, including space missions and agrivoltaic installations, showcasing their versatility and reliability [5]. - The company's research and development center and production facility are located in Thornton, Colorado [5].